TrialLancet (London, England)2025

Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.

Nisha R Acharya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.